DBV Technologies Investor Relations Material
Latest events
Q4 2023
DBV Technologies
Access the full event backlog
Slides, Transcripts, and Reports from 9,000+ public companies
Latest reports from DBV Technologies S.A.
Access all reports
DBV Technologies, S.A. is a clinical-stage biopharmaceutical company engaged in the research and development of epicutaneous immunotherapy (EPI) products to treat cancer and dermatology. The company's EPI technology platform includes monoclonal antibodies, passive transport devices using microelectrode arrays, and a wide variety of fully human anti-cancer antibodies
Latest articles
Sundar Pichai: CEO of Alphabet and Google
Explore Sundar Pichai's improbable journey from Chennai, India, to becoming one of the most powerful individuals on the planet.
19 Apr 2024
The Three Cornerstones of Serial Acquirer Success
Explore what is behind successful serial acquirers: efficient capital use, decentralization, and a strong focus on people.
19 Apr 2024
Companies That Had Their IPO in 2023: Cautious Optimism
The cautiously optimistic market in 2023 saw stocks rebounded upwards, and interest in IPOs picked up from the previous year.
15 Apr 2024
Ticker symbol
Country
🇫🇷 France